Want to see HK:9926 full AI Analyst Report?
9926 Stock Chart & Stats
HK$94.20
-HK$1.45(-1.47%)
At close: 4:00 PM EDT
HK$94.20
-HK$1.45(-1.47%)
Day’s Range― - ―
52-Week RangeHK$80.20 - HK$156.00
Previous CloseN/A
Volume607.00K
Average Volume (3M)9.98M
Market Cap
HK$86.02B
Enterprise ValueHK$75.92B
Total Cash (Recent Filing)HK$9.16B
Total Debt (Recent Filing)HK$4.98B
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Mar 31, 2027EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding941,143,200
10 Day Avg. Volume9,675,384
30 Day Avg. Volume9,979,598
Financial Highlights & Ratios
PEG Ratio-0.85
Price to Book (P/B)10.12
Price to Sales (P/S)30.78
P/FCF Ratio-50.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$153.10Price Target Upside62.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.28
Revenue Forecast (FY)HK$4.54B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginsRevenue rebounded strongly in 2025 while gross margins stayed in the mid-to-high 70% range, showing that the business can generate substantial gross profit from its therapies and partnerships. If sustained, this base can support continued investment in clinical development and commercialization.
Balance Sheet ResilienceA meaningfully larger equity base and moderate leverage provide Akeso with some balance-sheet resilience as it advances costly biotechnology programs. The improved debt-to-equity position versus 2024 may preserve financial flexibility, although continued losses could reduce that advantage over time.
Expanding Clinical PipelineStarting another Phase III study broadens cadonilimab beyond gastric, lung, and cervical cancers and increases the number of potential indications for the same asset. A broader late-stage pipeline can improve future commercialization opportunities and reduce reliance on one indication.
Bears Say
Deteriorating ProfitabilityThe shift from profit in 2023 to sizable losses in 2024 and 2025 shows that strong revenue and gross margins are not yet translating into sustainable earnings. Persistent negative operating margins can constrain internal funding and make results more dependent on successful pipeline execution.
Elevated Cash BurnNegative operating and increasingly negative free cash flow indicate that current spending and investment exceed cash receipts despite high gross profitability. Continued burn could require additional financing or tighter resource allocation, potentially limiting the pace at which Akeso develops and commercializes its pipeline.
Rising Debt And Funding PressureAlthough leverage remains moderate, rising total debt alongside negative returns on equity increases pressure on financial flexibility. If losses persist, debt obligations may compete with clinical and commercial investment, making capital allocation more difficult during the company’s development phase.
Akeso, Inc. News
9926 FAQ
What was Akeso, Inc.’s price range in the past 12 months?
Akeso, Inc. lowest stock price was HK$80.20 and its highest was HK$156.00 in the past 12 months.
What is Akeso, Inc.’s market cap?
Akeso, Inc.’s market cap is HK$86.02B.
When is Akeso, Inc.’s upcoming earnings report date?
Akeso, Inc.’s upcoming earnings report date is Mar 31, 2027 which is in 160 days.
How were Akeso, Inc.’s earnings last quarter?
Akeso, Inc. released its earnings results on Aug 27, 2026. The company reported -HK$0.539 earnings per share for the quarter.
Is Akeso, Inc. overvalued?
According to Wall Street analysts Akeso, Inc.’s price is currently Undervalued.
Does Akeso, Inc. pay dividends?
Akeso, Inc. does not currently pay dividends.
What is Akeso, Inc.’s EPS estimate?
Akeso, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Akeso, Inc. have?
Akeso, Inc. has 941,143,200 shares outstanding.
What happened to Akeso, Inc.’s price movement after its last earnings report?
Akeso, Inc. reported an EPS of -HK$0.539 in its last earnings report. Following the earnings report the stock price went up 7.431%.
Which hedge fund is a major shareholder of Akeso, Inc.?
Currently, no hedge funds are holding shares in HK:9926
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Akeso, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$153.10 (62.52% Upside)
HK$153.10 (62.52% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.38%
12-Months-Change
Fundamentals
Return on Equity
-10.86%
Trailing 12-Months
Asset Growth
28.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Akeso, Inc.
Akeso, Inc. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of therapeutic solutions. The company boasts a diverse pipeline, with a significant focus on oncology. Its cancer-focused treatments include AK104, a PD-1/CTLA-4 bi-specific antibody in development for various malignancies such as cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and other solid tumors. Another bi-specific antibody, AK112, targets PD-1/VEGF and is being developed for solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). Akeso also has several monoclonal antibodies in its oncology portfolio: AK105, a PD-1 monoclonal antibody, is aimed at NSCLC, NPC, relapsed/refractory classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma, thymic cancer, esophageal squamous cell carcinoma (ESCC), urothelial carcinoma (UC), GC, GEJ, cholangiocarcinoma, neuroendocrine tumors, and mismatch repair deficient solid tumors. AK117, a CD47 monoclonal antibody, is being investigated for myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, head and neck squamous cell carcinoma (HNSCC), R/R cHL, NPC, NSCLC, as well as general solid tumors and lymphomas. AK119, a CD73 monoclonal antibody, is under development for solid tumors. AK109, a VEGFR-2 monoclonal antibody, targets solid tumors and gastric cancer. Beyond oncology, Akeso is developing treatments for immunological and metabolic conditions: AK120, an IL-4R monoclonal antibody, for moderate-to-severe atopic dermatitis, asthma, and eosinophilic esophagitis. AK101, an IL-12/IL-23 monoclonal antibody, for moderate-to-severe psoriasis and ulcerative colitis. AK111, an IL-17 monoclonal antibody, for moderate-to-severe psoriasis and ankylosing spondylitis. AK102, a PCSK9 monoclonal antibody, designed to treat hypercholesterolemia. Its preclinical pipeline features AK127, a TIGIT monoclonal antibody for solid tumors, and AK115, an NGF monoclonal antibody. Akeso, Inc. collaborates with key partners including Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and the MD Anderson Medical Institute. The company was established in 2012 and operates from its headquarters in Zhongshan, People's Republic of China.
9926 Stock 12 Month Forecast
Average Price Target
HK$153.10
▲(62.52% Upside)
Technical Analysis
Innovent Biologics
―
Zai Lab Ltd
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―